XNAS
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.42 | -0.69 | -64.29% | $0 | ❌ Miss | -0.45% | -9.15% | — |
| 2026-03-26 | Q4 2025 | — | -5.72 | — | $0 | — | -1.59% | -10.87% | -6.67% |
Showing last 2 quarters.